Vetr upgraded shares of Johnson & Johnson (NYSE:JNJ) from a hold rating to a buy rating in a research report released on Wednesday, December 20th. They currently have $147.14 target price on the stock.
JNJ has been the subject of several other reports. Piper Jaffray Companies reiterated a hold rating and issued a $120.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 4th. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a hold rating in a report on Wednesday, October 18th. UBS Group restated a buy rating and set a $148.00 target price on shares of Johnson & Johnson in a report on Thursday, August 31st. Wells Fargo & Co upgraded shares of Johnson & Johnson from a market perform rating to an outperform rating and raised their target price for the stock from $140.00 to $149.00 in a report on Monday, October 9th. Finally, BMO Capital Markets upped their price target on shares of Johnson & Johnson to $161.00 and gave the company an outperform rating in a research report on Tuesday, December 12th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson has a consensus rating of Hold and an average price target of $145.94.
Johnson & Johnson (NYSE:JNJ) traded up $0.97 on Wednesday, reaching $145.76. 5,450,000 shares of the company traded hands, compared to its average volume of 5,920,000. The firm has a market capitalization of $391,590.00, a price-to-earnings ratio of 25.31, a price-to-earnings-growth ratio of 2.73 and a beta of 0.80. Johnson & Johnson has a 52-week low of $110.76 and a 52-week high of $146.42. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. Johnson & Johnson’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.68 EPS. equities analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.31%. Johnson & Johnson’s payout ratio is presently 58.33%.
Hedge funds and other institutional investors have recently bought and sold shares of the business. KCS Wealth Advisory bought a new position in Johnson & Johnson during the 4th quarter valued at about $455,000. Trellis Advisors LLC bought a new position in Johnson & Johnson during the 4th quarter valued at about $338,000. Hexavest Inc. lifted its holdings in Johnson & Johnson by 2.8% during the 4th quarter. Hexavest Inc. now owns 1,811,238 shares of the company’s stock valued at $253,066,000 after purchasing an additional 50,171 shares during the last quarter. Broadleaf Partners LLC bought a new position in Johnson & Johnson during the 4th quarter valued at about $894,000. Finally, Stillwater Capital Advisors LLC lifted its holdings in Johnson & Johnson by 17.4% during the 4th quarter. Stillwater Capital Advisors LLC now owns 102,918 shares of the company’s stock valued at $14,380,000 after purchasing an additional 15,277 shares during the last quarter. Institutional investors own 65.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/13/vetr-upgrades-johnson-johnson-jnj-to-buy.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.